Clascoterone vs Finasteride: A Detailed Comparison
Finasteride is the benchmark oral therapy for male androgenetic alopecia and has the deepest long-term dataset of any hair loss intervention. Clascoterone is topical, newer and mechanistically distinct. Understanding where each acts in the androgen pathway clarifies the entire comparison.
Two points in the same pathway
Testosterone is converted to DHT by the enzyme 5-alpha reductase. DHT then binds the androgen receptor in susceptible follicles and drives miniaturisation.
Finasteride inhibits type II 5-alpha reductase, reducing serum DHT substantially. Less DHT is produced, so less reaches the receptor — everywhere in the body.
Clascoterone leaves DHT production untouched and instead competes for the receptor in the tissue where it is applied, then is metabolised to an inactive compound once it enters circulation.
Side by side
| Clascoterone | Finasteride | |
|---|---|---|
| Mechanism | Androgen receptor antagonist | 5-alpha reductase type II inhibitor |
| Route | Topical | Oral (topical formulations exist) |
| Effect on serum DHT | Minimal by design | Substantial reduction |
| Action site | Local scalp tissue | Systemic |
| Evidence depth in alopecia | Emerging (Phase II/III) | Extensive, long-term |
| Typical concerns | Application-site reactions | Sexual and mood-related adverse effects in a minority |
The safety conversation
Finasteride's efficacy is not seriously disputed. The discussion centres on a minority of users who report sexual dysfunction, mood changes or persistent symptoms after discontinuation, which is what drives interest in alternatives that do not lower systemic DHT.
Clascoterone's topical design is a direct response to that concern: local receptor antagonism, rapid systemic inactivation. Its large acne trials showed predominantly mild, application-site adverse events. What it does not yet have is finasteride's decades of long-term follow-up in hair loss populations.
How the choice is usually framed
- Maximum evidence depth and established long-term study history — finasteride remains a common clinical reference.
- Preference to avoid systemic androgen suppression — topical receptor antagonism is the rationale for clascoterone.
- Women of childbearing potential — finasteride is contraindicated; any topical anti-androgen requires clinical supervision.
- Neither is a substitute for a diagnosis: confirm the pattern before treating it.
References
- Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. — Journal of the American Academy of Dermatology
- Hebert A, et al. Topical Clascoterone Cream 1%: Two Phase 3 Randomized Clinical Trials. — JAMA Dermatology, 2020
- Rosette C, et al. Clascoterone: a topical androgen receptor antagonist. — Journal of Drugs in Dermatology
This library is educational. For the product itself — formulation, routine, pricing and shipping terms — return to the main website.
View the product